Next Article in Journal
A Genome-Wide Association Study into the Aetiology of Congenital Solitary Functioning Kidney
Next Article in Special Issue
Prescriptions of Antipsychotics in Younger and Older Geriatric Patients with Polypharmacy, Their Safety, and the Impact of a Pharmaceutical-Medical Dialogue on Antipsychotic Use
Previous Article in Journal
Protective Effect of Fustin against Huntington’s Disease in 3-Nitropropionic Treated Rats via Downregulation of Oxidative Stress and Alteration in Neurotransmitters and Brain-Derived Neurotrophic Factor Activity
Previous Article in Special Issue
Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
 
 
Article
Peer-Review Record

Changes in Alprazolam Metabolism by CYP3A43 Mutants

Biomedicines 2022, 10(12), 3022; https://doi.org/10.3390/biomedicines10123022
by Jie Zhao 1,2, Sijie Liu 3, Clemens Alexander Wolf 3, Gerhard Wolber 3, Maria Kristina Parr 2,* and Matthias Bureik 1,*
Reviewer 1:
Reviewer 2: Anonymous
Biomedicines 2022, 10(12), 3022; https://doi.org/10.3390/biomedicines10123022
Submission received: 29 September 2022 / Revised: 3 November 2022 / Accepted: 6 November 2022 / Published: 23 November 2022
(This article belongs to the Special Issue Antipsychotics: 70 Years)

Round 1

Reviewer 1 Report

In the article entitled „Changes in alprazolam metabolism by CYP3A43 mutants”, the authors have done an excellent studying and explaining the difference in alprazolam metabolism by different CYP3A enzymes. I have just one comment:

1. The authors did not really explain the influence of the three CYP3A43 mutations (L293P, T409R, and P340A). The role of Ser119 and Gln105 is discussed, however the three mutations are not. I would really want to know the authors thoughts on this.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

This study titled 'Changes in alprazolam metabolism by CYP3A43 mutants" present important findings relating to the effects of polymorphism on the metabolic activity of CYP3A43. The results add to the current body of knowledge in this field and can help unearth several other unknown issues around the CYP3A family. 

The design of the study is generally sound and follows the template of similar studies. The use of alprazolam as probe substrate of CYP3A, along with the monitoring for the alpha and 4-hydroxy metabolites are well established. 

Some comments

1. The third paragraph of the introduction looks like a misfit. It does not appear relevant to the study. CYP3A43 plays roles in the metabolism of some antipsychotic agents. That is sufficient to say. What is missing is an in-depth presentation of CYP3A43, its polymorphism and potential implication for drug therapy. Also missing in the introduction is the scientific basis/justification of study, choice of methodology (e.g., alprazolam vs other substrates, why not olanzepine? mutant expression methodology, etc)

2. Are there any limitations to this findings, especially because of the use of, and reliance on docking to predict the metabolic activity of the isoforms? Are the mutants commercially available? 

3. Homology modeling of CYP3A43 was performed using CYP3A4 information. What does the 75.5% identity and 86.7% similarity between CYP3A4 and CYP3A43 mean? Is this activity, amino-acid sequence, or what? since the crystal structure of CYP3A43 is not publicly available.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop